Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181634 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
A Phase 2 study, sponsored by PrECOG.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT02181634 is a Phase 2 study that has completed, run by PrECOG. The registered enrollment target is 74 participants.
The verdict
NCT02181634, a Phase 2 study, has completed, sponsored by PrECOG.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy. The purpose of this study is to evaluate the effectiveness and safety of the combination of nab-paclitaxel and gemcitabine. The effectiveness will be determined by improvement in the length of time during and after treatment, that the CCA does not get worse.
Interventions
- DRUG Nab-Paclitaxel and Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2014-12-09 |
| Est. Completion | 2017-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02181634
The ClinicalTrials.gov registry entry for NCT02181634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nab-Paclitaxel and Gemcitabine is the first listed.
NCT02181634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02181634 about?
NCT02181634 is a clinical study titled "Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma". Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy. The purpose of this study is to evaluate the effectiveness and safety of the combination of nab-p...
What is the current status of trial NCT02181634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2014-12-09. Estimated completion is 2017-10-01.
What interventions are being tested in trial NCT02181634?
The interventions under investigation include: Nab-Paclitaxel and Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02181634?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.